Tag
DESTINY‑Breast04 shows trastuzumab deruxtecan (T‑DXd) significantly improves progression‑free and overall survival vs physician’s choice chemotherapy in HER2‑low metastatic breast cancer, with manageable safety and preserved patient‑reporte
Systematic review of 71 RCTs reveals that intra-articular hyaluronic acid injections offer initial symptom worsening but significant long-term relief, especially in early-stage knee osteoarthritis and older women; molecular weight’s role re
The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of
The PRO-DUCE randomized trial demonstrates that electronic symptom and vital sign monitoring during trastuzumab deruxtecan therapy can preserve quality of life in ERBB2-positive metastatic breast cancer patients, with notable improvements i
This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality with
A prospective study reveals that nearly 20% of surgical patients experience postoperative delirium in the PACU, with elevated preoperative anxiety significantly increasing this risk. Implementation of a brain health care bundle improves man
The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.
Sarilumab demonstrates significant improvement in disease control and quality of life for patients with relapsing polymyalgia rheumatica, enabling glucocorticoid sparing and sustained remission.
